Nivolumab
- Generic Name
- Nivolumab
- Brand Names
- Opdivo, Opdualag
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 946414-94-4
- Unique Ingredient Identifier
- 31YO63LBSN
- Background
Nivolumab is a fully human IgG4 antibody targeting the immune checkpoint programmed death receptor-1 (PD-1). This antibody was produced entirely in mice and grafted onto human kappa and IgG4 Fc region with the mutation S228P for additional stability and reduced variability. It was developed by Bristol Myers Squibb.
...
- Indication
Nivolumab is indicated to treat unresectable or metastatic melanoma, melanoma as adjuvant treatment, resectable or metastatic non-small cell lung cancer, small cell lung cancer, advanced renal cell carcinoma, classical Hodgkin lymphoma, squamous cell carcinoma of the head and neck, urothelial carcinoma, microsatellite instability-high or mismatch repair defi...
- Associated Conditions
- Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma, Advanced Gastric Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Advanced Renal Cell Carcinoma, Classical Hodgkin's Lymphoma, Completely resected Stage IIB melanoma, Completely resected Stage III melanoma, Completely resected Stage IV melanoma, Hepatocellular Carcinoma, Locally Advanced Hepatocellular Carcinoma, Locally Advanced Non-Small Cell Lung Cancer, Melanoma, Metastatic Colorectal Cancer (CRC), Metastatic Esophageal Adenocarcinoma, Metastatic Esophageal Squamous Cell Carcinoma, Metastatic Gastric Adenocarcinoma, Metastatic Gastric Cancers, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Hepatocellular Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Metastatic Renal Cell Carcinoma ( mRCC), Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC), Metastatic Urothelial Carcinoma (UC), Mismatch Repair-deficient (dMMR) Metastatic Colorectal Cancer (CRC), Muscle-invasive Urothelial Carcinoma, Poor Risk Advanced Renal Cell Cancer, Recurrent Non-small Cell Lung Cancer, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma, Relapsed or Refractory Classical Hodgkin's Lymphoma, Resectable Non-small Cell Lung Cancer, Stage IIB Melanoma, Stage IIC Melanoma, Unresectable Esophageal Squamous Cell Carcinoma, Unresectable Locally Advanced Urothelial Cancer, Unresectable Melanoma, Urothelial Carcinoma, Completely resected Stage IIC melanoma, Intermediate risk Advanced Renal Cell Cancer, Locally advanced Urothelial Carcinoma, Metastatic Microsatellite Instability High Colorectal Cancer, Metastatic Mismatch Repair Deficient Colorectal Cancer, Metastatic gastroesphageal juntion adenocarcinoma, Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN), Relapsed Classical Hodgkin's Lymphoma, Residual Esophageal Cancer, Residual Gastroesophageal Junction Cancer, Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma, Unresectable, advanced Esophageal Squamous Cell Carcinoma (ESCC), Unresectable, metastatic Esophageal Squamous Cell Carcinoma (ESCC), Unresectable, recurrent Esophageal Squamous Cell Carcinoma (ESCC)
- Associated Therapies
- Complete Surgical Resection, Neoadjuvant Therapies
Intradermal Ipilimumab and Nivolumab in High Risk Stage II Melanoma
- First Posted Date
- 2024-02-02
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 96
- Registration Number
- NCT06240143
- Locations
- 🇳🇱
Amsterdam University Medical Center, Amsterdam, Netherlands
🇳🇱Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands
🇳🇱University Medical Center Groningen, Groningen, Netherlands
Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab
- Conditions
- Interventions
- First Posted Date
- 2024-02-02
- Last Posted Date
- 2024-02-29
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 90
- Registration Number
- NCT06237920
- Locations
- 🇳🇱
NKI-AVL, Amsterdam, Noord-Holland, Netherlands
Drug Screening Using IMD in Bladder Cancer
- Conditions
- Interventions
- Device: Implantable Micro-DeviceDrug: MethotrexateDrug: CarboplatinDrug: AvelumabDrug: PaclitaxelDrug: VinblastineDrug: Gemcitabine/Cisplatin IDrug: Methotrexate/Vinblastine/Doxorubicin/Cisplatin/AvelumabDrug: Gemcitabine/Cisplatin IIDrug: CisplatinDrug: NivolumabDrug: PembrolizumabDrug: Gemcitabine/CarboplatinDrug: Methotrexate/Vinblastine/Doxorubicin/CisplatinDrug: Gemcitabine/Cisplatin/NivolumabDrug: ErdafitinibDrug: Paclitaxel/Docetaxel/IfosfamideDrug: GemcitabineDrug: Gemcitabine/Carboplatin/NivolumabDrug: EnfortumabDrug: Sacituzumab
- First Posted Date
- 2024-01-12
- Last Posted Date
- 2024-01-12
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 18
- Registration Number
- NCT06204614
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
- Conditions
- Advanced Esophageal AdenocarcinomaAdvanced Gastric AdenocarcinomaAdvanced Gastroesophageal Junction AdenocarcinomaClinical Stage II Esophageal Adenocarcinoma AJCC v8Clinical Stage III Esophageal Adenocarcinoma AJCC v8Clinical Stage III Gastric Cancer AJCC v8Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IV Esophageal Adenocarcinoma AJCC v8Clinical Stage IV Gastric Cancer AJCC v8Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
- Interventions
- First Posted Date
- 2024-01-12
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 224
- Registration Number
- NCT06203600
- Locations
- 🇺🇸
Kaiser Permanente-Anaheim, Anaheim, California, United States
🇺🇸Oklahoma Cancer Specialists and Research Institute-Tulsa, Tulsa, Oklahoma, United States
🇺🇸University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors (STELLAR-009)
- Conditions
- Interventions
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 140
- Registration Number
- NCT06191796
- Locations
- 🇺🇸
Exelixis Site #8, Los Angeles, California, United States
🇺🇸Exelixis Site #9, Miami, Florida, United States
🇺🇸Exelixis Clinical Site #1, Orlando, Florida, United States
Bevacizumab and ICIs + hSRT in Symptomatic Melanoma Brain Metastases
- Conditions
- Interventions
- First Posted Date
- 2023-12-11
- Last Posted Date
- 2023-12-27
- Lead Sponsor
- Melanoma and Skin Cancer Trials Limited
- Target Recruit Count
- 46
- Registration Number
- NCT06163820
A Study to Evaluate Treatment With Nivolumab Alone and Nivolumab Combined With Ipilimumab in Children With Melanoma
- First Posted Date
- 2023-12-08
- Last Posted Date
- 2024-04-18
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 100
- Registration Number
- NCT06163170
- Locations
- 🇺🇸
Cardinal Health, Dublin, Ohio, United States
Nivolumab Dose Optimization in Patients With a Complete, Partial or Stable Response
- First Posted Date
- 2023-11-03
- Last Posted Date
- 2024-04-22
- Lead Sponsor
- Erasmus Medical Center
- Target Recruit Count
- 34
- Registration Number
- NCT06116461
- Locations
- 🇳🇱
Erasmus MC, Rotterdam, Pending, Netherlands
IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
- Conditions
- Interventions
- First Posted Date
- 2023-11-01
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Immunocore Ltd
- Target Recruit Count
- 680
- Registration Number
- NCT06112314
- Locations
- 🇧🇷
Fundacao Pio XII - Hospital de Cancer de Barretos - Hospital de Amor, Barretos, Brazil
🇧🇷Centro de Pesquisas Oncologicas (CEPON), Florianópolis, Brazil
🇧🇷Pontificia Universidade Catolica do Rio Grande do Sul (PUCRS) - Hospital Sao Lucas - Centro de Pesquisa Clinica (CPC), Porto Alegre, Brazil
A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations
- Conditions
- Interventions
- First Posted Date
- 2023-10-26
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 100
- Registration Number
- NCT06101134
- Locations
- 🇺🇸
Local Institution - 0036, Issaquah, Washington, United States
🇺🇸Local Institution - 0030, Seattle, Washington, United States
🇬🇷Local Institution - 0019, Thessaloniki, B, Greece
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.